Rabbit Polyclonal AGPAT2 Antibody

+ +

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver tissue (A), colon carcinoma (B), lung carcinoma (C) and esophagus tissue (D), showing membrane localization using CK1 mouse mAb with DAB staining.    

  
  

AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2), also known as lysophosphatidic acid acyltransferase-β (LPAAT-β), is a key enzyme in the biosynthesis of glycerophospholipids and triglycerides. It catalyzes the acylation of lysophosphatidic acid (LPA) to phosphatidic acid (PA), the second step in the Kennedy pathway. This enzyme is predominantly expressed in metabolic tissues, including adipose tissue, liver, and small intestine, and plays a critical role in lipid metabolism and energy storage. Mutations in the AGPAT2 gene are linked to congenital generalized lipodystrophy type 1 (CGL1), a rare autosomal recessive disorder characterized by near-total loss of adipose tissue, severe insulin resistance, and metabolic complications.

AGPAT2 antibodies are essential tools for studying the enzyme's expression, localization, and function in both normal and pathological contexts. These antibodies enable detection of AGPAT2 protein levels in tissues or cultured cells via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use them to investigate mechanisms underlying lipid metabolism disorders, adipose tissue dysfunction, and metabolic syndromes. Additionally, AGPAT2 antibodies aid in diagnosing genetic lipodystrophies and evaluating therapeutic interventions targeting lipid biosynthesis pathways. Commercial AGPAT2 antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown to ensure reliable results in experimental models.